2 news items
Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results
MRVI
22 Feb 24
on management's current beliefs, expectations and assumptions regarding the future of Maravai's business, future plans and strategies, projections
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
DYAI
MRVI
13 Feb 24
of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining
- Prev
- 1
- Next